Human pathogenic hantaviruses and prevention of infection

References

• Kruger DH, Ulrich R, Lundkvist AH. Hantavirus infections and their prevention. Microbes Infect 2001; 3:1129 - 1144
   PubMed Web of Science ®Google Scholar
• Lee HW, van der GG. Hemorrhagic fever with renal syndrome. Prog Med Virol 1989; 36:62 - 102
   PubMedGoogle Scholar
• Mertz GJ, Hjelle B, Crowley M, Iwamoto G, Tomicic V, Vial PA. Diagnosis and treatment of new world hantavirus infections. Curr Opin Infect Dis 2006; 19:437 - 442
   PubMed Web of Science ®Google Scholar
• Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Annu Rev Med 1999; 50:531 - 545
   PubMed Web of Science ®Google Scholar
• Faber MS, Ulrich RG, Frank C, Brockmann SO, Pfaff GM, Jacob J, et al. Steep rise in notified hantavirus infections in Germany, April 2010. Euro Surveill 2010; 20:15
   Google Scholar
• Klempa B, Fichet-Calvet E, Lecompte E, Auste B, Aniskin V, Meisel H, et al. Hantavirus in African wood mouse, Guinea. Emerg Infect Dis 2006; 12:838 - 840
   PubMed Web of Science ®Google Scholar
• Klempa B, Koivogui L, Sylla O, Koulemou K, Auste B, Kruger DH, ter Meulen J. Serological evidence of human hantavirus infections in Guinea, West Africa. J Infect Dis 2010; 201:1031 - 1034
   PubMed Web of Science ®Google Scholar
• Schmaljohn CS, Nichol ST. Knipe DM, Howley PM. Bunyaviridae. Fields Virology 2007; 5:Philadelphia Lippencott Williams & Wilkins 1741 - 1789
   Google Scholar
• Klempa B, Tkachenko EA, Dzagurova TK, Yunicheva YV, Morozov VG, Okulova NM, et al. Hemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia. Emerg Infect Dis 2008; 14:617 - 625
   PubMed Web of Science ®Google Scholar
• Krüger DH, Klempa B. Liu D. Dobrava-Belgrade Virus. Molecular detection of human viral pathogens 2011; Boca Raton CRC Press 631 - 638
   Google Scholar
• Hooper JW, Ferro AM, Wahl-Jensen V. Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus. J Virol 2008; 82:1332 - 1338
   PubMed Web of Science ®Google Scholar
• Hammerbeck CD, Wahl-Jensen V, Hooper JW. Barrett ADT, Stanberry LR. Hantavirus. Vaccines for biodefense and emerging and neglected diseases 2009; London Academic Press/Elsevier 379 - 412
   Google Scholar
• Chaparro J, Vega J, Terry W, Vera JL, Barra B, Meyer R, et al. Assessment of person-to-person transmission of hantavirus pulmonary syndrome in a Chilean hospital setting. J Hosp Infect 1998; 40:281 - 285
   PubMed Web of Science ®Google Scholar
• Enria D, Padula P, Segura EL, Pini N, Edelstein A, Posse CR, Weissenbacher MC. Hantavirus pulmonary syndrome in Argentina. Possibility of person to person transmission. Medicina (B Aires) 1996; 56:709 - 711
   PubMed Web of Science ®Google Scholar
• Ferres M, Vial P, Marco C, Yanez L, Godoy P, Castillo C, et al. Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile. J Infect Dis 2007; 195:1563 - 1571
   PubMed Web of Science ®Google Scholar
• Martinez VP, Bellomo C, San Juan J, Pinna D, Forlenza R, Elder M, Padula PJ. Person-to-person transmission of Andes virus. Emerg Infect Dis 2005; 11:1848 - 1853
   PubMed Web of Science ®Google Scholar
• Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998; 241:323 - 330
   PubMed Web of Science ®Google Scholar
• Galeno H, Mora J, Villagra E, Fernandez J, Hernandez J, Mertz GJ, Ramirez E. First human isolate of Hantavirus (Andes virus) in the Americas. Emerg Infect Dis 2002; 8:657 - 661
   PubMed Web of Science ®Google Scholar
• Muranyi W, Bahr U, Zeier M, van der Woude FJ. Hantavirus infection. J Am Soc Nephrol 2005; 16:3669 - 3679
   PubMed Web of Science ®Google Scholar
• Kariwa H, Yoshimatsu K, Arikawa J. Hantavirus infection in East Asia. Comp Immunol Microbiol Infect Dis 2007; 30:341 - 356
   PubMed Web of Science ®Google Scholar
• Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on hantavirus ecology, epidemiology and disease. Clin Microbiol Rev 2010; 23:412 - 441
   PubMed Web of Science ®Google Scholar
• Maes P, Klempa B, Clement J, Matthijnssens J, Gajdusek DC, Kruger DH, Van Ranst M. A proposal for new criteria for the classification of hantaviruses, based on S and M segment protein sequences. Infect Genet Evol 2009; 9:813 - 820
   PubMed Web of Science ®Google Scholar
• Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA. Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses 2005; London Elsevier Academic Press
   Google Scholar
• Raftery MJ, Kraus AA, Ulrich R, Kruger DH, Schonrich G. Hantavirus infection of dendritic cells. J Virol 2002; 76:10724 - 10733
   Google Scholar
• Leduc JW, Ksiazek TG, Rossi CA, Dalrymple JM. A retrospective analysis of sera collected by the Hemorrhagic Fever Commission during the Korean Conflict. J Infect Dis 1990; 162:1182 - 1184
   PubMed Web of Science ®Google Scholar
• Alexeyev OA, Ahlm C, Billheden J, Settergren B, Wadell G, Juto P. Elevated levels of total and Puumala virus-specific immunoglobulin E in the Scandinavian type of hemorrhagic fever with renal syndrome. Clin Diagn Lab Immunol 1994; 1:269 - 272
   PubMedGoogle Scholar
• Markotic A, Dasic G, Gagro A, Sabioncello A, Rabatic S, Kuzman I, et al. Role of peripheral blood mononuclear cell (PBMC) phenotype changes in the pathogenesis of haemorrhagic fever with renal syndrome (HFRS). Clin Exp Immunol 1999; 115:329 - 334
   PubMed Web of Science ®Google Scholar
• Gott P, Zoller L, Darai G, Bautz EK. A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein. Virus Genes 1997; 14:31 - 40
   PubMed Web of Science ®Google Scholar
• Kallio-Kokko H, Lundkvist A, Plyusnin A, Avsic-Zupanc T, Vaheri A, Vapalahti O. Antigenic properties and diagnostic potential of recombinant Dobrava virus nucleocapsid protein. J Med Virol 2000; 61:266 - 274
   PubMed Web of Science ®Google Scholar
• Kallio-Kokko H, Leveelahti R, Brummer-Korvenkontio M, Lundkvist A, Vaheri A, Vapalahti O. Human immune response to Puumala virus glycoproteins and nucleocapsid protein expressed in mammalian cells. J Med Virol 2001; 65:605 - 613
   PubMed Web of Science ®Google Scholar
• Lundkvist A, Bjorsten S, Niklasson B, Ahlborg N. Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus: definition of epitopes specific for acute immunoglobulin G recognition in humans. Clin Diagn Lab Immunol 1995; 2:82 - 86
   PubMedGoogle Scholar
• Lundkvist A, Kallio-Kokko H, Sjolander KB, Lankinen H, Niklasson B, Vaheri A, Vapalahti O. Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. Virology 1996; 216:397 - 406
   PubMed Web of Science ®Google Scholar
• Lundkvist A, Vapalahti O, Plyusnin A, Sjolander KB, Niklasson B, Vaheri A. Characterization of Tula virus antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed nucleocapsid protein. Virus Res 1996; 45:29 - 44
   PubMed Web of Science ®Google Scholar
• Tischler ND, Galeno H, Rosemblatt M, Valenzuela PD. Human and rodent humoral immune responses to Andes virus structural proteins. Virology 2005; 334:319 - 326
   PubMed Web of Science ®Google Scholar
• Zoller L, Scholz J, Stohwasser R, Giebel LB, Sethi KK, Bautz EK, Darai G. Immunoblot analysis of the serological response in Hantavirus infections. J Med Virol 1989; 27:231 - 237
   PubMed Web of Science ®Google Scholar
• Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment and prevention. Viral Immunol 2004; 17:481 - 497
   PubMed Web of Science ®Google Scholar
• Yoshimatsu K, Yoo YC, Yoshida R, Ishihara C, Azuma I, Arikawa J. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins. Arch Virol 1993; 130:365 - 376
   PubMed Web of Science ®Google Scholar
• Valdivieso F, Vial P, Ferres M, Ye C, Goade D, Cuiza A, Hjelle B. Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection. Emerg Infect Dis 2006; 12:166 - 168
   PubMed Web of Science ®Google Scholar
• Ye C, Prescott J, Nofchissey R, Goade D, Hjelle B. Neutralizing antibodies and Sin Nombre virus RNA after recovery from hantavirus cardiopulmonary syndrome. Emerg Infect Dis 2004; 10:478 - 482
   PubMed Web of Science ®Google Scholar
• Horling J, Lundkvist A, Huggins JW, Niklasson B. Antibodies to Puumala virus in humans determined by neutralization test. J Virol Methods 1992; 39:139 - 147
   PubMed Web of Science ®Google Scholar
• Lundkvist A, Horling J, Niklasson B. The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays. Arch Virol 1993; 130:121 - 130
   PubMed Web of Science ®Google Scholar
• Manigold T, Mori A, Graumann R, Llop E, Simon V, Ferres M, et al. Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus. PLoS Pathog 2010; 6:1000779
   PubMed Web of Science ®Google Scholar
• Chu YK, Jennings G, Schmaljohn A, Elgh F, Hjelle B, Lee HW, et al. Cross-neutralization of hantaviruses with immune sera from experimentally infected animals and from hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome patients. J Infect Dis 1995; 172:1581 - 1584
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Thompson E, Schmaljohn CS. DNA vaccination with the Hantaan virus M gene protects Hamsters against three of four HFRS hantaviruses and elicits a high-titer neutralizing antibody response in Rhesus monkeys. J Virol 2001; 75:8469 - 8477
   PubMed Web of Science ®Google Scholar
• Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW. Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine. J Virol 2003; 77:9894 - 9905
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Smith J, Wahl-Jensen V. Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates. Virology 2006; 347:208 - 216
   PubMed Web of Science ®Google Scholar
• de Carvalho NC, Gonzalez D, Padula PV, Bjorling E, Plyusnin A, Lundkvist A. Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses. J Virol 2002; 76:6669 - 6677
   PubMed Web of Science ®Google Scholar
• Bharadwaj M, Nofchissey R, Goade D, Koster F, Hjelle B. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis 2000; 182:43 - 48
   PubMed Web of Science ®Google Scholar
• MacNeil A, Comer JA, Ksiazek TG, Rollin PE. Sin Nombre virus-specific immunoglobulin M and G kinetics in hantavirus pulmonary syndrome and the role played by serologic responses in predicting disease outcome. J Infect Dis 2010; 202:242 - 246
   PubMed Web of Science ®Google Scholar
• Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 1990; 64:3162 - 3170
   PubMed Web of Science ®Google Scholar
• Hooper JW, Kamrud KI, Elgh F, Custer D, Schmaljohn CS. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology 1999; 255:269 - 278
   PubMed Web of Science ®Google Scholar
• Pensiero MN, Jennings GB, Schmaljohn CS, Hay J. Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. J Virol 1988; 62:696 - 702
   PubMed Web of Science ®Google Scholar
• Xu X, Ruo SL, McCormick JB, Fisher-Hoch SP. Immunity to Hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins. Am J Trop Med Hyg 1992; 47:397 - 404
   PubMed Web of Science ®Google Scholar
• Klingstrom J, Stoltz M, Hardestam J, Ahlm C, Lundkvist A. Passive immunization protects cynomolgus macaques against Puumala hantavirus challenge. Antivir Ther 2008; 13:125 - 133
   PubMed Web of Science ®Google Scholar
• Huang C, Jin B, Wang M, Li E, Sun C. Hemorrhagic fever with renal syndrome: relationship between pathogenesis and cellular immunity. J Infect Dis 1994; 169:868 - 870
   PubMed Web of Science ®Google Scholar
• Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. J Immunol 2004; 172:3297 - 3304
   PubMed Web of Science ®Google Scholar
• Van Epps HL, Terajima M, Mustonen J, Arstila TP, Corey EA, Vaheri A, Ennis FA. Long-lived memory T lymphocyte responses after hantavirus infection. J Exp Med 2002; 196:579 - 588
   PubMed Web of Science ®Google Scholar
• Van Epps HL, Schmaljohn CS, Ennis FA. Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein. J Virol 1999; 73:5301 - 5308
   PubMed Web of Science ®Google Scholar
• Björkström NKL T, Stoltz M, Fauriat C, Braun M, Michaëlsson J, Klingström J, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011; 208:13 - 21
   PubMed Web of Science ®Google Scholar
• Wang PZ, Huang CX, Zhang Y, Li ZD, Yo HT, Zhang Y, et al. Analysis of the immune response to Hantaan virus nucleocapsid protein C-terminal-specific CD8(+) T cells in patients with hemorrhagic fever with renal syndrome. Viral Immunol 2009; 22:253 - 260
   PubMed Web of Science ®Google Scholar
• Kaukinen P, Vaheri A, Plyusnin A. Hantavirus nucleocapsid protein: a multifunctional molecule with both housekeeping and ambassadorial duties. Arch Virol 2005; 150:1693 - 1713
   PubMed Web of Science ®Google Scholar
• Sen N, Sen A, Mackow ER. Degrons at the C terminus of the pathogenic but not the nonpathogenic hantavirus G1 tail direct proteasomal degradation. J Virol 2007; 81:4323 - 4330
   PubMed Web of Science ®Google Scholar
• Safronetz D, Hegde NR, Ebihara H, Denton M, Kobinger GP, St JS, et al. Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with Andes virus. J Virol 2009; 83:7285 - 7295
   PubMed Web of Science ®Google Scholar
• Manigold T, Martinez J, Lazcano X, Ye C, Schwartz S, Cuiza A, et al. Case report: T-cell responses during clearance of Andes virus from blood cells 2 months after severe hantavirus cardiopulmonary syndrome. J Med Virol 2008; 80:1947 - 1951
   PubMed Web of Science ®Google Scholar
• Dargeviciute A, Brus SK, Sasnauskas K, Kruger DH, Meisel H, Ulrich R, Lundkvist A. Yeast-expressed Puumala hantavirus nucleocapsid protein induces protection in a bank vole model. Vaccine 2002; 20:3523 - 3531
   PubMed Web of Science ®Google Scholar
• Ulrich R, Lundkvist A, Meisel H, Koletzki D, Sjolander KB, Gelderblom HR, et al. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. Vaccine 1998; 16:272 - 280
   PubMed Web of Science ®Google Scholar
• Schonrich G, Rang A, Lutteke N, Raftery MJ, Charbonnel N, Ulrich RG. Hantavirus-induced immunity in rodent reservoirs and humans. Immunol Rev 2008; 225:163 - 189
   PubMed Web of Science ®Google Scholar
• Terajima M, Hayasaka D, Maeda K, Ennis FA. Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8+ T cells trigger capillary leakage in viral hemorrhagic fevers?. Immunol Lett 2007; 113:117 - 120
   PubMed Web of Science ®Google Scholar
• Wang M, Wang J, Zhu Y, Xu Z, Yang K, Yang A, Jin B. Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis 2009; 199:188 - 195
   PubMed Web of Science ®Google Scholar
• Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000; 18:275 - 308
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65 - 91
   PubMed Web of Science ®Google Scholar
• Makela S, Mustonen J, Ala-Houhala I, Hurme M, Partanen J, Vapalahti O, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. J Infect Dis 2002; 186:843 - 846
   PubMed Web of Science ®Google Scholar
• Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, Vaheri A. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney Int 1996; 49:217 - 221
   PubMed Web of Science ®Google Scholar
• Hjelle B. Vaccines against hantaviruses. Expert Rev Vaccines 2002; 1:373 - 384
   PubMedGoogle Scholar
• Maes P, Clement J, Van RM. Recent approaches in hantavirus vaccine development. Expert Rev Vaccines 2009; 8:67 - 76
   PubMed Web of Science ®Google Scholar
• Schmaljohn C. Vaccines for hantaviruses. Vaccine 2009; 27:61 - 64
   PubMed Web of Science ®Google Scholar
• Zhang YZ, Zou Y, Fu ZF, Plyusnin A. Hantavirus infections in humans and animals, China. Emerg Infect Dis 2010; 16:1195 - 1203
   PubMed Web of Science ®Google Scholar
• Boudreau E, Sellers K, Rusnak J, Rivard R, Bovnzi D, Joselyn M, et al. Phase 1 clinical study on the safety, tolerability and immunogenicity of Hantaan and Puumala DNA vaccines. Abstracts of the VIII International Conference on HFRS HPS and Hantavirus, Athens, Greece 2010; 83
   Google Scholar
• Li D. Trends of HFRS epidemiology and the expanded program on immunization with hantavirus vacccines in China. Abstracts of the VIII International Conference on HFRS HPS and Hantavirus, Athens, Greece 2010; 82
   Google Scholar
• Abu Daude NH, Kariwa H, Tkachenko E, Dzagurova T, Medvedkina O, Tkachenko P, et al. Genetic and antigenic analyses of a Puumala virus isolate as a potential vaccine strain. Jpn J Vet Res 2008; 56:151 - 165
   PubMed Web of Science ®Google Scholar
• Handke W, Oelschlegel R, Franke R, Wiedemann L, Kruger DH, Rang A. Generation and characterization of genetic reassortants between Puumala and Prospect Hill hantavirus in vitro. J Gen Virol 2010; 91:2351 - 2359
   PubMed Web of Science ®Google Scholar
• Yuan ZG, Li XM, Mahmmod YS, Wang XH, Xu HJ, Zhang XX. A single immunization with a recombinant canine adenovirus type 2 expressing the seoul virus Gn glycoprotein confers protective immunity against seoul virus in mice. Vaccine 2009; 27:5247 - 5251
   PubMed Web of Science ®Google Scholar
• Yuan ZG, Luo SJ, Xu HJ, Wang XH, Li J, Yuan LG, He LT, Zhang XX. Generation of E3-deleted canine adenovirus type 2 expressing the Gc glycoprotein of Seoul virus by gene insertion or deletion of related terminal region sequences. J Gen Virol 2010; 91:1764 - 1771
   PubMed Web of Science ®Google Scholar
• Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 1998; 50:141 - 182
   PubMed Web of Science ®Google Scholar
• Li C, Liu F, Liang M, Zhang Q, Wang X, Wang T, et al. Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice. Vaccine 2010; 28:4294 - 4300
   Google Scholar
• Severson WE, Schmaljohn CS, Javadian A, Jonsson CB. Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 2003; 77:481 - 488
   PubMed Web of Science ®Google Scholar
• Huggins JW, Kim GR, Brand OM, McKee KT Jr. Ribavirin therapy for Hantaan virus infection in suckling mice. J Infect Dis 1986; 153:489 - 497
   PubMed Web of Science ®Google Scholar
• Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, Wu ZO, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119 - 1127
   PubMed Web of Science ®Google Scholar
• Rusnak JM, Byrne WR, Chung KN, Gibbs PH, Kim TT, Boudreau EF, et al. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res 2009; 81:68 - 76
   PubMed Web of Science ®Google Scholar
• Chapman LE, Mertz GJ, Peters CJ, Jolson HM, Khan AS, Ksiazek TG, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Antivir Ther 1999; 4:211 - 219
   PubMed Web of Science ®Google Scholar
• Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, et al. Placebo-controlled, doubleb-lind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39:1307 - 1313
   PubMed Web of Science ®Google Scholar
• Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, et al. Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus. Antiviral Res 2008; 79:19 - 27
   PubMed Web of Science ®Google Scholar
• Chung DH, Strouse JJ, Sun Y, Arterburn JB, Parker WB, Jonsson CB. Synthesis and anti-Hantaan virus activity of N(1)-3-fluorophenyl-inosine. Antiviral Res 2009; 83:80 - 85
   PubMed Web of Science ®Google Scholar
• Hall PR, Malone L, Sillerud LO, Ye C, Hjelle BL, Larson RS. Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des 2007; 69:180 - 190
   PubMed Web of Science ®Google Scholar
• Larson RS, Brown DC, Ye C, Hjelle B. Peptide antagonists that inhibit Sin Nombre virus and hantaan virus entry through the beta3-integrin receptor. J Virol 2005; 79:7319 - 7326
   PubMed Web of Science ®Google Scholar
• Hall PR, Hjelle B, Brown DC, Ye C, Bondu-Hawkins V, Kilpatrick KA, Larson RS. Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade. Antimicrob Agents Chemother 2008; 52:2079 - 2088
   PubMed Web of Science ®Google Scholar
• Hall PR, Leitao A, Ye C, Kilpatrick K, Hjelle B, Oprea TI, Larson RS. Small molecule inhibitors of hantavirus infection. Bioorg Med Chem Lett 2010; 20:7085 - 7091
   PubMed Web of Science ®Google Scholar
• Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res 2008; 78:162 - 169
   PubMed Web of Science ®Google Scholar
• Groen J, Gerding M, Koeman JP, Roholl PJ, van Amerongen G, Jordans HG, et al. A macaque model for hantavirus infection. J Infect Dis 1995; 172:38 - 44
   PubMed Web of Science ®Google Scholar
• Sironen T, Klingstrom J, Vaheri A, Andersson LC, Lundkvist A, Plyusnin A. Pathology of Puumala hantavirus infection in macaques. PLoS One 2008; 3:3035
   PubMed Web of Science ®Google Scholar
• Hooper JW, Larsen T, Custer DM, Schmaljohn CS. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289:6 - 14
   PubMed Web of Science ®Google Scholar